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Emmy De Buck⇑, Nele S. Pauwels, Tessa Dieltjens, Veerle Compernolle, Philippe Vandekerckhove
Belgian Red Cross-Flanders, Motstraat 40, B-2800 Mechelen, BelgiumSummary IntroductionHemochromatosis is a disorder of the iron metabolism, character-
ized by high body iron content, necessitating frequent phleboto-
mies to remove excess iron. In some countries, this blood is
discarded and not used for blood transfusion because of the
non-voluntary character of this donation, and because a potential
risk of microbial contamination of the donor blood is assumed.
A systematic review was performed in order to collect and crit-
ically examine solid evidence with regard to the effectiveness and
safety of blood for transfusion when derived from hemochroma-
tosis patients who do not suffer from complications or organ
damage. Using three databases (The Cochrane Library, MEDLINE,
and Embase) we searched for studies from date of inception until
January 2012.
Out of 3470 articles, 80 references that were relevant to our
question were selected, including many opinion pieces, com-
ments, letters, and narrative reviews. Based on our selection cri-
teria, we ﬁnally retained only six observational studies, so
evidence on this subject is scarce and furthermore, the strength
of the available evidence is low to very low, due to poor study
designs. We found no evidence that red blood cell concentrates
from hemochromatosis patients without complications of iron
overload do not comply with the physiological quality require-
ments for transfusion, nor that their blood would present a
greater risk to recipient safety than blood from non-hemochro-
matosis donors. However, in vitro ﬁndings from two studies sug-
gest that iron-overloaded patients would be more susceptible to
bacterial growth, but future in vivo studies are warranted to con-
ﬁrm this.
Based on this, we call for harmonization of the blood donor
selection policy among countries allowing hemochromatosis
patients who do not suffer from complications of iron overload
to donate blood, once iron levels are normalized.
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by Elsevier B.V. All rights reserved.Journal of Hepatology 20
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E-mail address: emmy.debuck@rodekruis.be (E. De Buck).Hemochromatosis is characterized by entry of iron into the blood
stream inexcess of that required for erythropoiesis. Theexcess iron
can accumulate in parenchymal cells of liver, heart, endocrine
glands, and other tissues, and result in organ damage. Hemochro-
matosis is in most cases inherited (‘primary or hereditary hemo-
chromatosis’) as an autosomal recessive disorder, but can also be
acquired. It arises from alterations in genes that regulate the syn-
thesis of hepcidin, the latter downregulating the entry of iron into
the blood stream, andmany genotypes exist. Approximately 12.5%
of individuals ofNorthern Europeandescent are heterozygous for a
mutation in theHFE gene (High Fe) and almost one in two to three
hundredwhite people are homozygous. Based on genetic testing, it
became clear that although homozygotes most often display
abnormally high iron levels (high biochemical penetrance, ‘bio-
chemical hemochromatosis’), only a small number of them
develop complications and organdamage (low clinical penetrance,
‘clinical hemochromatosis’) [1–3].
The standard medical treatment for hemochromatosis is
removal of iron by regular therapeutic phlebotomy, either weekly
to return to safe blood levels of iron (iron depletion therapy) or
1–4 times a year (maintenance therapy) [4].
For many years, there has been a debate whether blood from
patients with hemochromatosis can be accepted for transfusion.
The two frequently raised arguments against the use of blood
from hemochromatosis patients are that: (1) the blood would
be unsafe and (2) the donation is not voluntary [5,6]. Concerning
the safety of the blood, there is fear of possible contamination
with siderophilic bacteria, such as Vibrio sp., Salmonella sp., and
Yersinia sp. [7–10], especially as Yersinia enterocolitica has been
identiﬁed with increased frequency as a causative agent of
post-transfusion septic shock with possible fatal outcome [11].
Because iron overload can impair the host immune system, and
viruses can interact with the iron metabolism to cause infection
(e.g., by altering the expression of proteins involved in iron
homeostasis), there is also a potential higher susceptibility for
viral infections [12–14]. The second argument deals with the fact
that hemochromatosis patients that donate blood are not consid-
ered to be voluntary non-remunerated donors because they ben-
eﬁt from the donation. Since the phlebotomy is free of charge,
becoming blood donor may be a cheap alternative for physician
visits thus providing a ﬁnancial incentive. In addition, the neces-
sity of phlebotomy does not qualify this donation as ‘‘voluntary’’
[15].12 vol. 57 j 1126–1134
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The management and cost of hemochromatosis treatment and
the use of blood obtained via phlebotomy vary strongly through-
out the Western world [16]. In many countries, mainly Europe,
blood from hemochromatosis patients is drawn only for thera-
peutic reasons and cannot be used for blood transfusion because
of both arguments described above. The concern with regard to
the voluntary nature of the donation however, can be addressed
by rigorous use of the donor medical questionnaire, rejecting the
blood for further use if the criteria applicable to any other donor
are not met. In addition, making all phlebotomies free to hemo-
chromatosis patients could eliminate any ﬁnancial incentives
and thus the non-voluntary character of the donation.
Because it is not clear whether the assumed risk for contam-
ination of blood from hemochromatosis patients is based on sci-
entiﬁc evidence and the Belgian Red Cross-Flanders Blood Service
seeks to improve a qualitative blood supply based on evidence-
based policies, we focused on this argument and addressed the
question whether blood of uncomplicated hemochromatosis
patients is safe and effective for blood transfusion. Furthermore,
this question is also relevant for the convenience of therapy
and the satisfaction/sense of contribution of hemochromatosis
patients. Therefore, a systematic review of the literature was per-
formed. The rationale for performing this systematic review is
summarized in Key Points 1.
Key Points 1 
Rationale for reviewing this question 
• Relevant existing blood transfusion guidelines are not 
uniform and are based on opinion and consensus rather 
than on solid evidence
• Available red blood cell units are often limited 
• This question is also relevant for the quality and 
convenience of therapy and a sense of contribution of 
hemochromatosis patients 
• The Belgian Red Cross-Flanders Blood Service seeks to 
improve a qualitative blood supply based on evidence-
based policies
Materials and methodsSearch strategy
All searches for evidence were performed between December
2011 and January 2012. The following sources were searched:
The Cochrane Database of Systematic Reviews, The Database of
Abstracts of Reviews of Effects, The Cochrane Central Register
of Controlled Trials, MEDLINE (using the PubMed interface), and
Embase (using the Embase.com interface).
The following search formula was used for searching
MEDLINE:
1. ‘‘Hemochromatosis’’ [Mesh] OR ‘‘hemochromatosis’’ [TIAB] OR
‘‘haemochromatosis’’ [TIAB]
2. ‘‘Blood Donors’’ [Mesh] OR ‘‘Blood Transfusion’’ [Mesh]
3. ‘‘Blood Safety’’ [Mesh] OR ‘‘Blood-Borne pathogens’’ [Mesh] OR
‘‘infection’’ [TIAB] OR ‘‘safety’’ [TIAB]
4. ‘‘Virus Diseases’’ [Mesh] OR ‘‘transfusion transmissible’’ [TIAB]Journal of Hepatology 20125. ‘‘Bacterial Infections’’ [Mesh] OR ‘‘Bacteremia’’ [Mesh]
6. ‘‘Erythrocytes’’ [Mesh] OR ‘‘Erythrocyte Indices’’ [Mesh] OR
‘‘Erythrocyte Count’’ [Mesh] OR ‘‘quality’’ [TIAB] OR ‘‘mean
corpuscular volume’’ [TIAB] OR ‘‘mean cell volume’’ [TIAB]
OR ‘‘cell count’’ [TIAB] OR ‘‘mean cell hemoglobin’’ [TIAB] OR
‘‘MCV’’ [TIAB] OR ‘‘MCH’’ [TIAB]
7. 2–6 OR
8. 1 AND 7
The following search formula was used in Embase:
1. ‘hemochromatosis’/exp OR hemochromatosis:ab:ti OR
haemochromatosis:ab:ti
2. ‘blood donor’/exp OR ‘blood transfusion’/exp
3. ‘blood safety’/exp OR infection:ab:ti OR safety:ab:ti
4. ‘virus infection’/exp OR ‘transfusion transmissible’:ab:ti
5. ‘bloodborne bacterium’/exp OR ‘bacterial infection’/exp OR
‘bacteremia’/exp
6. ‘erythrocyte’/exp OR ‘mean corpuscular volume’/exp OR
‘erythrocyte count’/exp OR quality:ab:ti OR ‘mean corpuscular
volume’:ab:ti OR ‘mean cell volume’:ab:ti OR ‘cell count’:ab:ti
OR ‘mean cell hemoglobin’:ab:ti OR ‘MCV’:ab:ti OR ‘MCH’:ab:ti
7. 2–6 OR
8. 1 AND 7
Selection of the studies was performed in parallel by two
independent reviewers (E.D.B., N.S.P.). Titles and abstracts of
the studies identiﬁed by the search were scanned. When a study
met the eligibility criteria, full text articles were obtained. Studies
that did not meet the in- and exclusion criteria were excluded.
The citation lists of included studies were searched for additional
related articles, the ﬁrst 20 related items in PubMed were
scanned for other potentially relevant studies, and the references
by which the included studies were cited were screened. The ﬁnal
selection of articles was compared among the two reviewers. Dis-
agreement on the selection of studies was resolved by discussion
or by involving a third reviewer (T.D.).
Study selection/inclusion and exclusion criteria
Language
Studies in English and French were included.
Types of studies
Randomized controlled trials, controlled clinical trials, cohort
studies, case–control studies, and case-series were included. In
vitro studies were included if a control group was used and if the
blood or serum sample was tested in unprocessed form (no incu-
bation or cultivation of speciﬁc cell types). Excluded study designs
were narrative reviews, commentaries, letters and opinions.
Types of participants
We included studies with a population that represents our target
population: hemochromatosis patients without complications of
iron overload that need phlebotomies to treat or maintain their
condition and that are eligible as a blood donor. In detail, the
included population consists of hereditary hemochromatosis
patients without organ damage but having abnormal serum ferri-
tin levels or undergoing iron depletion or maintenance therapy
(‘biochemical hemochromatosis’). Excluded population: patients
with complications of iron overload or organ damage (‘clinicalvol. 57 j 1126–1134 1127
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hemochromatosis’); peoplewithpositive genetic testing for hemo-
chromatosis, but without any indication of increased iron levels;
patients with secondary, neonatal or juvenile hemochromatosis.
Intervention and comparison
Intervention: Blood from hemochromatosis patients; Compari-
son: Blood from healthy donors; blood from hemochromatosis
patients at different time points.
Types of outcome measures
Primary outcomes: (1) safety: markers of transfusion-transmissi-
ble diseases or viral or bacterial infections in blood from persons
who receive blood from a hemochromatosis patient; (2) effec-
tiveness: erythrocyte properties/hematologic variables in blood
from blood acceptors who receive blood from a hemochromatosis
patient. Secondary outcomes: (1) safety: markers of transfusion-
transmissible diseases or viral or bacterial infections in blood
from hemochromatosis patients; (2) effectiveness: erythrocyte
properties/hematologic variables in blood or serum samples from
hemochromatosis patients.
Data collection
Data concerning study design, study population, outcome mea-
sures and study ﬁndings were extracted and tabulated in addition
to the limitations in study design by two independent reviewers
(E.D.B., N.S.P.). In case of disagreement a third reviewer was
involved (T.D.).
Quality of evidence
The GRADE approach was used to grade the overall quality of evi-
dence included in this review. GRADE considers limitations in
study design of the included studies, inconsistency between the
different studies (due to differences in populations, interventions
or outcomes), indirectness (of population, intervention or out-
come), imprecision and publication bias. Limitations in study
design were analyzed by evaluating the presence of eligibility cri-
teria, adequate control of confounding, design-speciﬁc sources of
bias and correct measurement of exposure and outcome. The
quality of evidence can be downgraded for each of the previousPotentially relevant 
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Fig. 1. Flowchart of identiﬁcation and selection of studies.
1128 Journal of Hepatology 2012quality criteria and ﬁnally results in high, moderate, low or very
low grade of evidence [17].Results
Study characteristics
Fig. 1 provides a ﬂowchart of the identiﬁcation and selection of
studies. The reviewers screened 3470 citations, including 164
duplicates and one triplicate. Evaluation of titles and abstracts
resulted in 80 references. After full text evaluation, 74 studies
were excluded because selection criteria were not met. It is
remarkable that half of the studies that were selected for full text
evaluation did not meet the criteria because of the study design.
Many reviews, comments, letters and case reports are published
on this subject, but very few studies exist to support them. Table 1
displays an overview of all studies that were excluded based on
the criteria for population, intervention or outcome, with the rea-
son for exclusion [18–43]. Only six references [44–49] met the
inclusion criteria and were available for analysis (Table 2). All
included studies were observational studies, three of them were
performed in the United States, two in France and one in The
Netherlands. One study measured blood effectiveness by deter-
mining hematologic variables [44]. Five studies measured safety
(agents of viral or bacterial transfusion-transmissible disease).
Among the latter, two studies investigated the prevalence of viral
infections [45,46], including one screening 52,650 blood donors
(hemochromatosis patients and regular donors) and another
investigating 130 hemochromatosis patients before and after
blood donation (without control group). Furthermore, three
studies were included evaluating the prevalence of bacterial
infections in hemochromatosis patients and healthy people (not
donating blood) [47–49]. Study characteristics and a detailed
description of the populations can be found in Table 2.
Quality of evidence
All included studies were observational studies, including one
case-series, which results in an initial ‘low level of evidence’. In
three out of the six studies, risk of bias was found because of lim-cluded based on title and abstract evaluation, 
cates, n = 164
ates, n = 1
ible, n = 3224
cluded based on full text evaluation, 
ailable studies, n = 2
er language, n = 6
 design criteria, n = 40
lation criteria, n = 17
ention criteria, n = 5
me criteria, n = 4
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Table 1. Excluded studies based on the selection criteria for population (P), intervention (I) or outcome (O), with the reason for exclusion.
Reference Reason for exclusion
Adams et al., 1997 [18] O prevalence of symptoms; serum ferritin level
Barton et al., 1999 [19] O eligibility for being blood donor; reasons for ineligibility are only given for the patient group and not for the 
control group
Barton et al., 2000 [20] P patients with complications of iron overload were not excluded
Bell et al., 1997 [21] P the population is based on genetic screening and is a mixed population [with normal and increased ferritin 
levels, patients with complications of iron overload are not excluded]
Beutler et al., 2006 [22] P the population is based on a genetic screening and is a mixed population [with normal and increased ferritin 
levels, patients with complications of iron overload are not excluded]
Blacklock et al., 2000 
[23]
I no control group
Bove et al., 2011 [24] P the population is based on genetic screening and is a mixed population [with normal and increased ferritin 
levels, patients with complications of iron overload are not excluded]
Brandão et al., 2005 
[25]
P mixed population, patients with liver cirrhosis and persons with normal ferritin concentrations are included
De Filippi et al., 1998 
[26]
P only 8% have a normal liver
De Gobbi et al., 2004 
[27]
P the population is based on genetic screening and is a mixed population [with normal and increased ferritin 
levels, patients with complications of iron overload are not excluded]
Del Castillo et al., 2009 
[28]
I no control group
Deugnier et al., 1991 
[29]
P in probands [n = 224] GH diagnosis was based on the following data: [a] absence of anemia and hemolytic 
disease; [b] classical clinical signs of genetic hemochromatosis; and [c] liver iron overload assessed on liver 
biopsy
Edwards et al., 1988 
[30]
P the population is based on genetic screening and is a mixed population [with normal and increased ferritin 
levels, patients with complications of iron overload are not excluded]
Feeney et al., 2005 [31] P mixed population, persons with normal ferritin levels are included
Levstik et al., 1998 [32] I no control group
Mah et al., 2005 [33] P patients with chronic hepatitis B and C
McLaren et al., 2007 
[34]
P the population is based on genetic screening and is a mixed population [with normal and increased ferritin 
levels, patients with complications of iron overload are not excluded]
McDonnell et al., 1999 
[35]
O prevalence of symptoms
Olakanmi et al., 2007 
[36]
P no information on the population 
Lee et al., 1999 [37] P patients with clinical hemochromatosis
Power et al., 2004 [38] I no control group
Røsvik et al., 2010 [39] O serum ferritin level
Sendi et al., 2005 [40] P no proven ferritin increase
Shan et al., 2005 [41] P hemochromatosis patients excluded
Silva et al., 2005 [42] I no control group
Wise et al., 2010 [43] P not clear
JOURNAL OF HEPATOLOGYitations in design: one study had high risk of recall bias [46],
another had lack of clearly deﬁned in-/exclusion criteria [49],
and a third study did not include a control group (case-series)
[45]. We did ﬁnd consistency across the different studies. We also
addressed indirectness: all studies included the study population
of interest, but two of the six studies were in vitro studies, and all
studies included secondary outcomes. Due to the limited number
of included studies, it was difﬁcult to evaluate publication bias.
Because of limitations in design in three out of the six studies
and the case-series design in one study, we did not upgrade the
strength of the body of evidence. Overall, the strength of the body
of evidence, based on the GRADE approach, is low to very low. An
overview of the limitations in design of the individual studies is
summarized in Table 2.Journal of Hepatology 2012Synthesis of ﬁndings
One study evaluated parameters that give an indication of the
effectiveness of blood of hemochromatosis patients for the pur-
pose of blood transfusion [44]. In this study, cell concentrates
from hemochromatosis patients and regular donors were col-
lected and stored up to 50 days. Samples were taken for analysis
at the beginning and weekly thereafter. The outcome of interest
was the mean cell volume (MCV): it was shown that red blood
cells (RBCs) of hemochromatosis patients at time of collection
had a larger MCV (mean, 99.4 fL; range, 87.4–105.6 fL) than the
RBCs of regular donors (MCV; mean, 92.3 fL; range, 86.1–
98.1 fL). This is probably due to the overall younger cell age of
RBCs of hemochromatosis patients. In addition, during storage,vol. 57 j 1126–1134 1129
Table 2. Characteristics and main results of included studies.
Study 
(country) 
[Ref.]
Design Patient characteristics Outcome Findings Limitations
in design
Luten et al., 
2008 (The 
Netherlands)
[44]
Observational 
study
Eight hemochromatosis patients with proven 
iron-overload and 15 regular donors; patient 
characteristics: transferrin saturation ≥50%; 
serum ferritin level ≥700 µg/L
Several hematologic, biophysi-
cal, and biochemical variables 
in red blood cell concentrates,  
and weekly thereafter during 
the storage period of 50 days
between hemochromatosis 
and regular donors 
None
Sanchez 
et al., 2001 
(United 
States)
[46]
Observational 
study
52,650 blood donors from eight different US 
blood centres, including 197 hemochro-
matosis patients; patient characteristics: 
patients are suitable as blood donors acc- 
ording to the deferral criteria used by eight
large US blood centers; patients are not in a 
period during which they require phleboto-
my to treat their condition; ferritin levels are 
not available
Unreported deferrable risks 
based on anonymous mail 
survey.
Screening for antibody to 
hepatitis B core antigen 
(anti-HBc), syphilis, human 
hepatitis C virus (HCV), hepa-
titis B surface antigen (HBsAg) 
and human T-lymphotropic 
virus (HTV) in blood samples
-
ferences between hemochro-
matosis and regular donors 
Recall bias in 
anonymous 
mail survey. No 
limitations in 
the screening
Leitman et al., 
2003 (United 
States)
[45]
Observational 
study (case-
series)
130 hemochromatosis patients; patient 
characteristics: laboratory evidence of iron 
overload; ferritin >50 µg/L; patients are suit-
able as blood donors according to the FDA 
eligibility criteria
Seroconversions for agents 
of transfusion-transmissible 
serial donations (weekly to 
every 8 weeks, based on fer-
ritin levels), during the study 
period of 27 months
No incident seroconversions 
for agents of transfusion-
transmissible disease 
occurred 
No control 
group
Jolivet-
Gougeon 
et al., 2008 
(France)
[47]
In vitro study 26 iron-overloaded (homozygous C282Y 
mutation), 35 iron-depleted hemochromato-
sis patients and 33 healthy control subjects; 
patient characteristics: no included subjects 
exhibited diabetes, cardiomyopathy, non-
none received any antimicrobial treatment; 
ferritin: iron-overloaded group: 1118.38 µg/L 
± 1096.75 µg/L; iron-depleted group: 21.29 
µg/L ± 11.85 µg/L; control group: 108.03 
µg/L ± 82.36 µg/L
Antibacterial activity of serum 
samples against Salmonella 
typhimurium LT2
decrease for iron-overloaded 
hemochromatosis patients 
compared to iron-depleted 
patients and controls. No 
difference for iron-depleted 
patients versus controls
None
Jolivet-
Gougeon 
et al., 2007 
(France)
[48]
Observational 
study
236 male hemochromatosis patients 
(C282Y/C282Y) and 303 blood donors; 
patient characteristics: average of iron 
and ferritin serum concentrations was 
25 ± 10 µmol/L (5.2-48) and 235 ± 581 
µg/L (6-4520), respectively. None of the 
hemochromatosis patients exhibited 
state, concomitant infection or immunity 
treatment (to preclude false-positive and 
-negative serological reactions)
Antibodies against several 
serogroups of Yersinia 
pseudotuberculosis (I to V) 
and Yersinia enterocolitica 
(O:3, O:9 O:5.27) in serum 
samples
hemochromatosis patients 
compared to control blood 
donors
None 
Bullen et al., 
1991 (United 
states)
[49]
In vitro study Five iron-overloaded hemochromatosis 
patients and five healthy people; patient 
characteristics: 
hemochromatosis who were undergoing 
phlebotomy for therapeutic reasons
Survival of 
the blood samples, measured 
by mixing the blood with a 
suspension of  
bacteria
difference in survival: no 
survival in normal blood for 
inoculum 10³/ml or less, 
while bacteria grew rapidly 
in blood samples from iron-
overloaded hemochromatosis 
patients 
Lack of 
inclusion and 
exclusion 
criteria
No significant differences  
from the first week of storage
No statistically significant dif
immunodeficiency virus (HIV),
disease (not specified) during
specific inflammatory states, and concomi-
tant infection or immune deficiency, and
diabetes, cardiomyopathy, inflammatory
deficiency and none received antimicrobial
five patients with
No significant increase for
Statistically significant
Statistically significantVibrio vulnificus in
V. vulnificus
Reviewthe MCV of RBCs increased in both groups in a similar way with
10–15%. No clinically relevant signiﬁcant differences could be
found between the two groups for a large number of biochemical
and biophysical variables including extracellular glucose concen-
tration, extracellular concentration of sodium and potassium ions,
intracellular 2,3-DPG levels, cellular ATP concentration, total
adenylate content, pO2, pCO2, pH, and bicarbonate. Based on this1130 Journal of Hepatology 2012study, it can be concluded that there is no evidence that blood
derived from hemochromatosis patients does not comply with
the quality requirements, and therefore is suitable for the purpose
of blood transfusion from a hemato-physiological point of view.
With regard to the safety of the blood, two studies evaluated
transfusion-transmissible viral infections, one study measured
antibacterial antibodies and two other in vitro studies tested sus-vol. 57 j 1126–1134
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ceptibility of the blood against bacteria. Based on an email survey
ﬁlled in by blood donors fromeight different US blood centers [46],
it was concluded that there is no statistically signiﬁcant different
prevalence of unreported deferrable risks (risk factors for transfu-
sion-transmissible viral infections that should result in deferral if
reported during donor screening) between hemochromatosis
donors (during maintenance therapy) and donors reporting no
medical conditions necessitating phlebotomy (prevalence 2.0%
versus 3.1%, respectively). Based on laboratory screening tests,
including screening for antibody to hepatitis B core antigen, syph-
ilis, human immunodeﬁciency virus, hepatitis C virus, hepatitis B
surface antigen, and human T-lymphotropic virus, no statistically
signiﬁcant difference could be found for hemochromatosis donors
versus regular donors (overall prevalence of positive screening test
results of 1.3% versus 1.6%, respectively).
A second study analyzed 130 hemochromatosis patients with
laboratory evidence of iron overload. Of these, 76% met FDA eligi-
bility criteria applied for blood donation. Based on the ferritin
level, phlebotomywas performedweekly to every 8 weeks, during
a study period of 27 months. In every blood sample, serologic test-
ing for (not speciﬁed) agents of transfusion-transmissible disease
was performed and no incident seroconversions for agents of
transfusion-transmissible disease occurred during this period
[45]. The ﬁndings from the latter two studies suggest that hemo-
chromatosis patients do not present a greater risk to blood safety
than other donors, at least with regard to viral infections.
In three observational studies, including two in vitro studies,
antibacterial activity of blood of hemochromatosis patients was
compared with blood of regular donors. No signiﬁcant increase in
antibodies against several serogroups of Yersinia pseudotuberculo-
sis (I to V) and Yersinia enterocolitica (O:3, O:9, O:5.27) could be
found in the serum of hemochromatosis patients without compli-
cations (average iron concentration of 25 lmol/L (5.2–48) and fer-
ritin 235 lg/L (6–4520), absence of diabetes, cardiomyopathy,
inﬂammatory state, concomitant infection or immunity deﬁ-
ciency) as compared to control blood donors [48]. Furthermore,
in blood samples from iron-depleted hemochromatosis patients,
antibacterial activity against Salmonella typhimurium LT2 was
shown to be the same as in samples from healthy donors [47]. In
contrast, it was shown that there is a statistically signiﬁcant
decreased antibacterial activity against S. typhimurium LT2 and a
better survival of Vibrio vulniﬁcus in blood from iron-overloaded
hemochromatosis patients when compared with samples from
healthy people [47–49].
In summary, there is no evidence showing that blood from
uncomplicated hemochromatosis patients would be unsafe to
use as donor blood. Moreover, the available evidence supports
the use of blood from hemochromatosis patients for blood trans-
fusions, at least after normalization of their ferritin status. Since
two in vitro studies suggest that blood obtained from iron-over-
loaded patients would be more susceptible for bacterial growth,
further studies are warranted here. An overview of the ﬁndings
per study can be found in Table 2.
Discussion
Hemochromatosis patients need frequent therapeutic phleboto-
mies. In some countries, this blood is discarded and not used
for transfusions because of the non-voluntary character of the
donation and the assumption that this blood would be less safe
with regard to the possible presence of viral or bacterial con-Journal of Hepatology 2012taminations. In this article, we show that there is no evidence
that this blood after normalization of the iron level is not safe
for blood transfusion. Study selection was limited to studies
describing the target population, i.e. hemochromatosis patients
that apart from their known diagnosis, would otherwise be eli-
gible to donate blood based on the other exclusion criteria for
donors in general. Since irreversible organ damage is such an
exclusion criterion, we did not take this subgroup of hemo-
chromatosis patients into account.
Evidence is scarce concerning this subject: from 3470 poten-
tially relevant studies, we selected 80 studies that were relevant
to the question, and retained only six studies that met the selec-
tion criteria. The reason for the low number of published studies
may be (1) the low prevalence of transfusion-related infections,
which necessitates large scale and long term studies, (2) logistic
problems, implicating the follow-up of patients receiving the
blood, or may be (3) ethical, because potentially unsafe blood
should be transfused.
Furthermore, the quality of the evidence available in the six
included studies is low to very low. We downgraded the level of
evidence due to indirectness, because all studies measured sec-
ondary outcomes. It would have been of greater interest to mea-
sure outcomes in patients receiving the blood (which we deﬁned
as primary outcome), however, such studies are lacking in the lit-
erature. One study measured blood effectiveness by determining
hematologic variables, and for this study therewere no limitations
in design [44]. Two studiesmeasured the prevalence of viral infec-
tions [45,46], including a study without control group (case-ser-
ies), testing blood samples from 130 hemochromatosis patients
[45]. Taking into account the very low incidence of transfusion-
transmissible viral infections, this represents a very low number
of test persons, which is a serious limitation in design. The other
three selected studies evaluated the prevalence of bacterial infec-
tions, and at ﬁrst sight the results of these studies were not consis-
tent. In two in vitro studies it was shown that a higher risk for
bacterial contamination is present in blood from iron-overloaded,
but not from iron-depleted patients [47,49]. In a third study, the
presence of anti-Yersinia antibodies in the blood of uncomplicated
hemochromatosis patients was compared to control blood donors,
and no signiﬁcant difference could be found [48]. In this study, it is
not clearly stated whether the included patients where iron-over-
loaded or iron-depleted. Because none of them had complications,
presumably only a minority of the study group is in the iron-over-
loaded stage, and thus the results are in agreement with these of
the other studies. Based on in vitro ﬁndings with iron-overloaded
patients, and in the absence of more solid evidence concerning
the risk of viral and bacterial infections in this subset of hemochro-
matosis patients, conclusions about accepting hemochromatosis
patients as blood donors should be cautious and take into account
the normalization of the iron level.
In addition to the evidence, current practice also seems to sup-
port this ﬁnding. Because of the high prevalence of hereditary
hemochromatosis in the general population, there is no doubt that
in current practice of blood donations (with no routine testing of
hemochromatosis parameters, as ferritin and transferrin satura-
tion, nor of genetic testing), a substantial number of donations
originate from carriers of the hemochromatosis gene. Until now,
this practice has never resulted in documented serious adverse
events in patients transfused with these blood products.
Apart from concerns with regard to the safety of the blood of
hemochromatosis patients, the non-altruistic character of thevol. 57 j 1126–1134 1131
Key Points 3 
Gaps in evidence and future research
• Solid evidence is scarce concerning this subject. 
Reasons could be: the low prevalence of transfusion-
related infections (which would result in large scale 
and long term studies); ethical reasons (transfusing 
potentially unsafe blood); logistic problems (follow-up of 
patients receiving the blood)
• Studies evaluating safety and effectiveness of blood 
transfusions with blood from hemochromatosis patients 
are lacking. Future research should  this gap in by
follow-up studies from patients who received blood from 
hemochromatosis patients
fill
Review
donation remains a potential argument for exclusion of hemo-
chromatosis patients [5,6]. However, using the donor medical
questionnaire in a rigorous way, rejecting the blood for further
use if all donor criteria are not met, should address this concern.
One way to eliminate potential ﬁnancial incentives is by making
all phlebotomies free to hemochromatosis patients, a measure
that is already taken in some countries [15].
In recent years, the British, French, German, and Swedish
transfusion services already changed their policy with regard
to hemochromatosis patients who require continued phleboto-
mies. In France, a multidisciplinary working group studied the
subject in 2001, and re-evaluated the eligibility criteria for
hemochromatosis patients as blood donors, because the discov-
ery of the HFE gene in 1996 made it clear that hemochromato-
sis exists in many different variants [50]. Similar measures
have been taken, outside Europe, in the US, Canada, and Aus-
tralia [4,51–54], where hemochromatosis donor blood is being
used for transfusion. However, increased hemovigilance is
required in their operating policies and because of these logis-
tical consequences, collection of hemochromatosis donor blood
is still not implemented worldwide [55].
Combining the available evidence and experiences from daily
practice, we conclude that there is no reason supporting the
exclusion of these patients, after normalization of their ferritin
status and in the absence of organ damage, from the donor pool.
Although not decisive in donor acceptance policy, accepting these
patients into the donor pool is also relevant for the quality and
convenience of therapy, and for the satisfaction or sense of contri-
bution of these patients as advocated by hemochromatosis
patient groups. In Key Points 2, we summarize how we used the
principles of Evidence-Based Practice (evidence, practice experi-
ence and preferences) to address our initial question [56].Key Points 2 
Addressing this question using the three principles of 
Evidence-Based Practice
• Best available evidence: a systematic review of 
evidence resulted in only six (all of them observational, 
including two in vitro studies) studies amongst 3470 
studies contained any evidence showing that blood from 
uncomplicated iron-depleted hemochromatosis patients, 
would be unsafe to use as donor blood
• Practical experience and expert opinion: in several 
countries hemochromatosis blood is being used for 
transfusion, and many unknown hemochromatosis 
patients are blood donors anyway. No adverse effects 
have been reported so far
• Patient’s values and expectations: including these 
patients into the donor pool is also relevant to the 
quality and convenience of therapy of hemochromatosis 
patients and for the satisfaction or sense of contribution 
of these patients as advocated by hemochromatosis 
patient groups
• Based on these three pillars, a call for harmonization 
of the use of blood of uncomplicated iron-depleted 
hemochromatosis patients as donor blood is warranted
potentially relevant studies identified. None of these
1132 Journal of Hepatology 2012In conclusion, the variance in policy that exists in and
between many countries today calls for a harmonization of
the use of the blood of hemochromatosis patients that have
no complications of iron overload and have normalized iron lev-
els, allowing them to be accepted as blood donors. However,
taking into account that only a limited number of studies are
available, future research is necessary. In particular, the suscep-
tibility to infections of iron-overloaded patients should be
addressed as this would reveal whether we can also use blood
from uncomplicated patients who still have high ferritin levels,
i.e., who are still in the iron removal stage and need more fre-
quent phlebotomies. Follow-up studies on patients who
received blood from hemochromatosis donors hence is a prior-
ity; furthermore, studying other blood products such as plate-
lets and plasma from hemochromatosis donors would be
interesting (Key Points 3).• The evidence obtained was retrieved from in vitro and 
observational studies, so more robust study types are 
needed. For example, future studies should in 
vivo, the in vitro  of increased susceptibility to
infections of iron-overloaded patients 
• The available evidence does only provide evidence 
on transfusion with red blood cells and not other blood 
products. Therefore, future research should also focus 
on other blood products such as platelets and plasma 
preparations
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